Form 4: Madrigal Pharmaceuticals Director Fred B. Craves Sells Shares
SEC Form 4 Filing
Director Fred B. Craves of Madrigal Pharmaceuticals sold a total of 3,400 shares of common stock in multiple transactions on November 25, 2024.
Summary
- Fred B. Craves, a director at Madrigal Pharmaceuticals, sold 2,200 shares of common stock at a weighted average price of $350.0775 per share on November 25, 2024.
- He also sold an additional 1,200 shares of common stock at a weighted average price of $350.7146 per share on the same day.
- These sales were executed in multiple transactions within the price ranges of $350.00 to $350.40 and $350.46 to $351.06, respectively.
- Following these transactions, Mr. Craves directly owns 360,076 shares and indirectly owns 27,071 shares through various entities.
- The indirect holdings include shares held through the Craves Family Foundation, a grantor retained annuity trust, and Bay City Capital LLC.
Sentiment
Score: 5
Explanation: The document is a neutral report of insider trading activity, with no inherent positive or negative sentiment. It's a routine filing.
Risks
- Sales by insiders can sometimes be perceived negatively by the market, potentially impacting the stock price.
Industry Context
This is a routine filing related to insider trading activity and is common for publicly traded companies. It provides transparency into the transactions of company insiders.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
- The reported transactions are typical for directors who may periodically adjust their holdings for personal financial reasons.
- The price ranges and weighted average prices are within normal market fluctuations for a stock like Madrigal Pharmaceuticals.
Stakeholder Impact
- Shareholders may be interested in the insider trading activity, but the impact is likely to be minimal given the relatively small number of shares sold.
Key Dates
| Date | Description |
|---|---|
| 11/25/2024 | Date of the stock sales by Fred B. Craves. |
| 11/27/2024 | Date the Form 4 was signed. |
Keywords
Madrigal Pharmaceuticals, Fred B. Craves, insider trading, stock sale, share transaction, director, MDGL
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.